Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27110)	12/31/1998 4:47:00 PM
From: Arthur Radley	Respond to of 32384

I wasn't looking at after market trading but nice to see that the bias is still up.

To: Henry Niman who wrote (27110)	12/31/1998 4:53:00 PM
From: aknahow	Read Replies (1) \| Respond to of 32384

Should 1999 see a biotech anyone is interested in propose a change in domicile to Bermuda or other tax haven, I suggest that one not automatically be against such a change. Biotechs have a tough time raising funds and a change in domicile for companies with the potential to generate non U.S. sales and profits such a change might increase cash flow at a critical time. I mention this since, unfortunately for some a change in domicile may be an emotional issue rather than a dollars and cents issue. I personally hope LGND, CORR and others will study this issue and decide to change domicile in 1999. One biotech has successfully done this in 1998. M. Murphy did not oppose a specific change but he said, "It's not a big deal" IMO he was wrong. Outside of the science of a company such a domicile change is a real big deal and we all must eventually understand that it's not just science, as a biotech must be financially viable.